Non-Cochrane · intervention · PM42278933

Effect of Melatonin as an Adjunct to NSPT on Periodontal and Systemic Outcomes in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of RCTs.

Angelopoulou Thaleia, Bobetsis Yiorgos A · Journal of clinical medicine · 2026 · PubMed · doi:10.3390/jcm15114071

Findings

Population Patients with type 2 diabetes mellitus and periodontitis

7 findings

Systemic melatonin (oral tablets, 6 mg/day for 8 weeks) as an adjunct to NSPTNSPT plus placeboCAL (clinical attachment level), change from baseline
8 weeks post-treatment · Periodontal clinics (Iran, Romania)
SMD -1.49 [-2.03, -0.95]
Low
Downgraded: risk of bias, imprecision
2 studies · 94 participants
Systemic melatonin (oral tablets, 6 mg/day for 8 weeks) as an adjunct to NSPTNSPT plus placeboSerum IL-6, change from baseline
8 weeks post-treatment · Periodontal clinics (Iran, Romania)
SMD -5.04 [-13.97, 3.89]
Low
Downgraded: risk of bias, imprecision
2 studies · 94 participants
Systemic melatonin (oral tablets, 6 mg/day for 8 weeks) as an adjunct to NSPTNSPT plus placeboSerum TAC (total antioxidant capacity), change from baseline
8 weeks post-treatment · Periodontal clinics (Iran, Romania)
SMD 0.08 [-0.05, 0.20]
Low
Downgraded: risk of bias, imprecision
2 studies · 94 participants
Systemic melatonin (oral tablets, 6 mg/day for 8 weeks) as an adjunct to NSPTNSPT plus placeboSerum hs-CRP, change from baseline
8 weeks post-treatment · Periodontal clinics (Iran, Romania)
SMD -0.97 [-1.22, -0.73]
Low
Downgraded: risk of bias, imprecision
2 studies · 94 participants
Systemic melatonin (oral tablets, 6 mg/day for 8 weeks) as an adjunct to NSPTNSPT plus placeboPPD (probing pocket depth), change from baseline
8 weeks post-treatment · Periodontal clinics (Iran, Romania)
SMD -1.99 [-2.54, -1.43]
Low
Downgraded: risk of bias, imprecision
2 studies · 94 participants
Systemic melatonin (oral tablets, 6 mg/day for 8 weeks) as an adjunct to NSPTNSPT plus placeboHbA1c, change from baseline
8 weeks post-treatment · Periodontal clinics (Iran, Romania)
SMD -1.15 [-1.63, -0.68]
Low
Downgraded: risk of bias, imprecision
2 studies · 94 participants
Systemic melatonin (oral tablets, 6 mg/day for 8 weeks) as an adjunct to NSPTNSPT plus placeboSerum TNF-alpha, change from baseline
8 weeks post-treatment · Periodontal clinics (Iran, Romania)
SMD -0.51 [-1.92, 0.90]
Low
Downgraded: risk of bias, imprecision
2 studies · 94 participants

Included primary studies 3

Open in Studies
StudyYearAlso included byOutcomes it informs hereTrial data
Anton 2021
Study on the Effects of Melatonin on Glycemic Control and Periodontal Parameters in Patients with Type II Diabetes Mellitus and…
PMID:33562452
20211 other reviewnot statednot extracted yet
Bazyar 2019
The effects of melatonin supplementation in adjunct with non-surgical periodontal therapy on periodontal status, serum melatonin and…
PMID:30328031
2019this review onlynot statednot extracted yet
Sarac Gul 2024
Melatonin supports nonsurgical periodontal treatment in patients with Type 2 diabetes mellitus and periodontitis: A randomized clinical…
PMID:38055628
2024this review onlynot statednot extracted yet

Overlap with other reviews

Reviews that include the same primary studies are not independent evidence. Shared counts match studies by PMID, DOI or NCT, and otherwise by author and year (a probable match). Only the non-Cochrane dental reviews have study lists, so overlap with Cochrane reviews is not counted yet.

Review question

ElementPlanned (methods)Found (results)
PopulationAdults (18 years or older) with periodontitis and confirmed type 2 diabetes mellitusPatients with T2DM and periodontitis (n=149 in 3 RCTs; n=94 in 2 pooled RCTs)
InterventionSystemic melatonin as an adjunct to NSPTOral melatonin 6 mg/day plus NSPT (n=75)
ComparisonNSPT alone or NSPT plus placeboNSPT plus placebo (2 RCTs) or NSPT alone (1 RCT) (n=74)
OutcomesPrimary: clinical periodontal parameters (PPD, CAL, gingival inflammation, plaque). Secondary: biochemical periodontal parameters; systemic glycemic control, oxidative stress and inflammationPPD, CAL, BoP, GI, PI, GCF MMP-8, RANKL, OPG, HbA1c, FBG, serum TAC, hs-CRP, TNF-alpha, IL-6, IL-1beta, MDA, SOD, CAT, GPx, TOS
Study designsRandomized controlled trialsRCTs (3)
TimingMinimum follow-up of 1.5 months8 weeks (pooled); 3 and 6 months (one trial)